This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
milla1cf Thu, 03/28/2024 - 07:30 March 28, 2024 — Medtronic plc, a global leader in healthcare technology, announced that the United States Food and Drug Administration ( FDA ) has approved the Evolut FX+ transcatheter aorticvalve replacement (TAVR) system for the treatment of symptomatic severe aorticstenosis.
Circulation: Cardiovascular Interventions, Ahead of Print. Some patients with aorticstenosis may require multiple valve interventions in their lifetime, and choosing transcatheter aorticvalve replacement (TAVR) as the initial intervention may be appealing to many.
Circulation: Cardiovascular Interventions, Ahead of Print. BACKGROUND:Current guidelines recommend surgical aorticvalve replacement (SAVR) for patients with severe aorticstenosis and unfavorable iliofemoral access.
Circulation: Cardiovascular Interventions, Ahead of Print. BACKGROUND:Data concerning the outcomes of transcatheter aorticvalve replacement in type 0 bicuspid aorticstenosis (AS) are scarce. Self-expanding transcatheter heart valves were used in the majority of patients (n=1160; 91.4%).
Circulation: Cardiovascular Imaging, Volume 17, Issue 12 , Page e017425, December 1, 2024. BACKGROUND:In aorticstenosis, the myocardium responds with left ventricular hypertrophy, which is characterized by increased left ventricular mass due to cellular hypertrophy and extracellular matrix expansion. weeks post-AVR.
Circulation: Cardiovascular Imaging, Ahead of Print. BACKGROUND:Patients with paradoxical low-flow, low-gradient severe aorticstenosis exhibit low transvalvular flow rate (Q), while maintaining preserved left ventricular ejection fraction. Subgroups were based on MR severity (severe and nonsevere). P<0.001).
Circulation, Ahead of Print. The groups were stratified by aorticvalve morphology (BAV, n=589; TAV, n=558). The outcomes of interests were new-onset third-degree AV block or new-onset LBBB during the index hospitalization.
Circulation, Volume 150, Issue Suppl_1 , Page A4145296-A4145296, November 12, 2024. Aorticvalvestenosis (AS) is often a contraindication to liver transplantation (LT). There was a similar change in mean gradients whereas aorticvalve area and dimensionless index remained unchanged after LT.
Circulation: Cardiovascular Interventions, Volume 16, Issue 11 , Page e012966, November 1, 2023. Transcatheter aorticvalve replacement (TAVR) is increasingly being performed in younger and lower surgical risk patients.
BackgroundCardiac fibrosis is common in patients with severe aorticstenosis and an independent predictor of death. Combined with highsensitivity cardiac troponin T, circulating TIMP1 should be incorporated into risk stratification to identify patients undergoing TAVR who are at a higher risk of death. 95% CI, 2.69.7];P<0.001)
Circulation, Ahead of Print. Background: Symptomatic severe aorticstenosis (AS) remains undertreated with high resultant mortality despite increased growth and availability of aorticvalve replacement (AVR) since the advent of transcatheter therapies. cm2were enrolled. cm2were enrolled. with EPN versus 37.2%
Circulation, Ahead of Print. Background:The optimal treatment in patients with severe aorticstenosis (AS) and small aortic annulus (SAA) remains to be determined.
Circulation, Ahead of Print. Severe disease is managed with valve replacement procedures, which entail high health care–related costs and postprocedural morbidity and mortality. Valvular heart disease is a common cause of morbidity and mortality worldwide and has no effective medical therapy.
Our perspectives on aorticstenosis (AS) are changing. Novel approaches are developing to address this through: (1) screening with circulating biomarkers; (2) development of drugs to slow disease progression and (3) early valve intervention guided by medical imaging.
Objectives This study aimed to evaluate the prognostic value of coronary microvascular dysfunction (CMD) at long term after transcatheter aorticvalve implantation (TAVI) and to explore its relationship with extravalvular cardiac damage (EVCD). CMD was defined as IMR angio ≥30 units.
Lp(a) is emerging as an important, yet under-recognized, potential risk factor for cardiovascular disease due to its ability to promote the development of plaques within artery walls, clot formation and aorticvalve calcification. Circulation. 2022 Aug, 80 (9) 934946 Kronenberg F. Arnett DK et al. 2019 Sep 10;140(11):e563-e595.
Circulation: Cardiovascular Interventions, Ahead of Print. Background:Frailty associates with worse outcomes after transcatheter aorticvalve replacement (TAVR). Cross-sectional muscle (psoas and paraspinal) areas were measured on computed tomography and indexed to height. per 1 SD decrease [95% CI, 1.15–1.89];P=0.002)
Circulation: Cardiovascular Interventions, Ahead of Print. Background:Atherosclerotic cardiovascular disease (ASCVD) is highly prevalent in patients with severe aorticstenosis undergoing transcatheter aorticvalve replacement (TAVR).
Circulation, Ahead of Print. Background: Atrial fibrillation (AF) is common in patients undergoing transcatheter aorticvalve replacement (TAVR) and is associated with increased risk of bleeding and stroke. For the composite primary endpoint, TAVR+.LAAO LAAO was non-inferior to TAVR+ medical therapy (22.7
Lipoprotein(a) (Lp[a]) can improve the accuracy of assessment of atherosclerotic cardiovascular disease and the risk of aorticvalvestenosis. Currently, there is no specific treatment to lower its circulating concentration. Raised Lp(a) is a feature of familial hypercholesterolaemia.
Circulation: Cardiovascular Quality and Outcomes, Ahead of Print. The primary outcome was a composite of all-cause mortality or hospital readmission within 1 year.
Circulation, Ahead of Print. BACKGROUND:High circulating levels of Lp(a) (lipoprotein[a]) increase the risk of atherosclerosis and calcific aorticvalve disease, affecting millions of patients worldwide.
The diagnostic coronary angiogram identified only minimal coronary artery disease, but there was a severely calcified, ‘immobile’ aorticvalve. Aortic angiogram did not reveal aortic dissection. If you see this, you should Doppler the valve. In fact, bedside ultrasound might even find severe aorticstenosis.
SMART 4 ( NCT04722250 ) studied patients with severe aorticstenosis and a small aortic annulus who underwent transcatheter aorticvalve replacement (TAVR). A total of 716 patients underwent TAVR with either a self-expanding supraannular valve or a balloon-expandable valve. It is able to deliver 3.5L/min
Circulation, Ahead of Print. A peak systolic pulmonary artery pressure >60 mm Hg during exercise has been associated with an increased risk of cardiovascular death, heart failure rehospitalization, and aorticvalve replacement in aorticvalvestenosis. P=0.001), E/e’ at rest (OR per SD, 1.61;P=0.012),
Circulation: Cardiovascular Imaging, Ahead of Print. BACKGROUND:Aortic valve calcification (AVC) has been shown to be a powerful assessment of aorticstenosis (AS) severity and a predictor of adverse outcomes. However, its accuracy in patients with low-flow AS has not yet been proven.
Adult Cardiac Surgery Database Lead Author Title Publication Date Jacob Raphael Red Blood Cell Transfusion and Pulmonary Complications: The Society of Thoracic Surgeons Adult Cardiac Surgery Database Analysis The Annals of Thoracic Surgery January 2024 Joseph Sabik Multi-Arterial versus Single-Arterial Coronary Surgery: Ten Year Follow-up of One Million (..)
Program Designations Access and Publications (A&P) 1 Participant User File (PUF) 2 Task Force on Funded Research (TFR) 3 Special Projects 4 Adult Cardiac Surgery Database Lead Author Title Publication Date William Keeling 2 National Trends in Emergency Coronary Artery Bypass Grafting European Journal of Cardiothoracic Surgery October 2023 Jake (..)
(MedPage Today) -- The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued to show promise for slowing the progression of fibrocalcific aorticvalvestenosis in phase I and II studies. Circulation) The extent of myocardial.
More troponin values were measured at the cardiac center: 2327- 267 ng/L 0821- 355 ng/L 1108- 305 ng/L An echocardiogram on day three of the patients admission showed an ejection fraction of 46% with abnormal basal inferior and basal lateral segments, and severe aorticstenosis. What "initiates" the aorticstenosis cascade?
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content